Sign In
Buy SPRY
$7.74
-0.200 (-2.52%)
At Close: Jul 13, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
05:35pm, Thursday, 09'th Jul 2026
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or the "Company") (NASDAQ: SPRY). Such investors are advised t
Can ARS Pharma's New CEO Unlock Neffy's Potential?
01:37pm, Thursday, 09'th Jul 2026
On Tuesday, ARS Pharmaceuticals Inc. (NASDAQ:SPRY) announced a leadership transition. Co-founder and CEO Richard Lowenthal stepped down as an employee and officer, effective July 6, 2026.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
05:38pm, Tuesday, 07'th Jul 2026
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or the "Company") (NASDAQ: SPRY). Such investors are advise
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
05:38pm, Tuesday, 07'th Jul 2026
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY). Such investors ar
ARS Pharmaceuticals Announces CEO Succession
04:30pm, Tuesday, 07'th Jul 2026
Richard Lowenthal, Chief Executive Officer, Transitioning following More than a Decade of Leadership Since Co-Founding the Company
ARS Pharmaceuticals (SPRY) Securities Fraud Investigation - Levi & Korsinsky
02:00pm, Monday, 06'th Jul 2026
ARS Pharmaceuticals stock lost more than 23% of its value in a single after-hours session after Neffy® failed to secure any new formulary additions in the July 2026 payer cycle -- a result that contr
SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraud
10:07am, Wednesday, 01'st Jul 2026
NEW YORK--(BUSINESS WIRE)--Shareholders who held ARS Pharmaceuticals (NASDAQ: SPRY) stock watched the value drop more than 23% in after-hours trading on June 24, 2026, after the Company disclosed that
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
04:45pm, Tuesday, 30'th Jun 2026
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY). Such investors
ARS Pharmaceuticals Investigation Initiated: Levi and Korsinsky Investigates the Officers and Directors of ARS Pharmaceuticals (SPRY)
ARS Pharmaceuticals CEO projected CVS Caremark formulary inclusion was expected for the July 1, 2026 commercial formulary cycle -- the July 2026 payer cycle produced zero new formulary additions, and
SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
12:00pm, Sunday, 28'th Jun 2026
[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmac
SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
11:54am, Sunday, 28'th Jun 2026
LOS ANGELES--(BUSINESS WIRE)---- $SPRY--SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm.
ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins
01:32pm, Thursday, 25'th Jun 2026
ARS Pharmaceuticals Inc. (NASDAQ:SPRY) on Wednesday reaffirmed its expectation to achieve cash-flow breakeven in 2027, even as no additional commercial formulary decisions for its epinephrine nasal sp
ARS Pharma Collapses After CVS Punts Its Epinephrine Spray Decision To January
10:04am, Thursday, 25'th Jun 2026
ARS Pharmaceuticals stock collapsed Thursday after CVS Caremark declined to add its epinephrine spray, Neffy, to its formulary.
ARS Pharmaceuticals Provides Commercial and Financial Updates
04:05pm, Wednesday, 24'th Jun 2026
No new commercial formulary additions or coverage decisions issued for neffy (epinephrine nasal spray) in the July 1, 2026 cycle; company to continue payer discussions for potential future inclusion
